Crinetics Pharmaceuticals Inc (CRNX)Healthcare | Biotechnology | San Diego, United States |
USD
|
Hot Take ↕ | Oct. 10, 2026, 1:37 p.m. UTC
The immediate outlook is neutral due to a lack of statistical data to confirm momentum, despite the stock trading near its 52-week high. However, the long-term investment case is severely compromised by deteriorating fundamentals; the company is burning significant cash with negative operating margins and negative returns on equity, while the market has already priced in a massive revenue surge that leaves the valuation extremely stretched at over 200x sales. With no dividend to provide income and a balance sheet showing substantial free cash outflows, the security lacks the safety margin required for a buy recommendation. |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 3.959 |
| Revenue per Share | 0.423 |
| Market Cap | 9,012,787,200 |
| Forward P/E | -21.17 |
| Beta | 0.09 |
| Website | https://www.crinetics.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 1.4985294 |
| Address1 | 6,055 Lusk Boulevard |
| All Time High | 85.01 |
| All Time Low | 10.63 |
| Ask | 85.03 |
| Ask Size | 300 |
| Audit Risk | 3 |
| Average Daily Volume10 Day | 2,404,560 |
| Average Volume | 4,385,151 |
| Average Volume10Days | 2,404,560 |
| Beta | 0.088 |
| Bid | 84.92 |
| Bid Size | 1,000 |
| Board Risk | 6 |
| Book Value | 11.265 |
| City | San Diego |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Currency | USD |
| Current Price | 84.95 |
| Current Ratio | 15.571 |
| Date Short Interest | 1,786,665,600 |
| Day High | 85.01 |
| Day Low | 84.92 |
| Debt To Equity | 3.959 |
| Ebitda | -544,849,984 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -14.411 |
| Enterprise To Revenue | 186.252 |
| Enterprise Value | 7,851,659,264 |
| Exchange | NMS |
| Exchange Timezone Name | UTC |
| Fifty Day Average | 76.9278 |
| Fifty Two Week High | 85.01 |
| Fifty Two Week Low | 32.3 |
| Financial Currency | USD |
| First Trade Date Epoch Utc | 1,784,295,000 |
| Float Shares | 95,500,072 |
| Forward Eps | -4.11833 |
| Forward P E | -21.169441 |
| Free Cashflow | -248,761,632 |
| Full Time Employees | 594 |
| Fullday Change | 0.0 |
| Fullday Change Percent | 0.0 |
| Fullday Price | 84.95 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,788,220,800 |
| Gross Margins | 0.0 |
| Gross Profits | -334,721,984 |
| Held Percent Insiders | 0.01134 |
| Held Percent Institutions | 1.19214 |
| Implied Shares Outstanding | 106,095,205 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and cushing's disease; and CRN09682, a nonpeptide drug conjugate for SST2 positive solid tumors. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease; and SST3 Agonist program for the treatment of polycystic kidney disease, as well as Oral GLP-1 and Oral GIP nonpeptides for the treatment of obesity. The company has an agreement with Sanwa Kagaku Kenkyusho Co., Ltd to develop and commercialize Paltusotine in Japan, and Cellular Longevity, Inc. to develop and commercialize CRN01941, a somatostatin receptor type 2 agonist. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California. |
| Long Name | Crinetics Pharmaceuticals Inc |
| Market Cap | 9,012,787,200 |
| Max Age | 86,400 |
| Message Board Id | finmb_280584191 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -501,606,016 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 9,012,787,664 |
| Number Of Analyst Opinions | 8 |
| Open | 84.96 |
| Operating Cashflow | -422,515,008 |
| Operating Margins | -5.27347 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 858 450 6464 |
| Previous Close | 84.95 |
| Price Hint | 2 |
| Price To Book | 7.5410557 |
| Price To Sales Trailing12 Months | 213.79607 |
| Profit Margins | 0.0 |
| Quick Ratio | 15.238 |
| Quote Type | EQUITY |
| Recommendation Key | hold |
| Recommendation Mean | 2.77778 |
| Regular Market Day High | 85.01 |
| Regular Market Day Low | 84.92 |
| Regular Market Open | 84.96 |
| Regular Market Previous Close | 84.95 |
| Regular Market Volume | 8,182,078 |
| Return On Assets | -0.26283002 |
| Return On Equity | -0.42446 |
| Revenue Growth | 23.363 |
| Revenue Per Share | 0.423 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 106,095,205 |
| Shares Percent Shares Out | 0.0621 |
| Shares Short | 6,588,676 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 6,212,042 |
| Short Name | Crinetics Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.0726 |
| Short Ratio | 2.26 |
| State | CA |
| Symbol | CRNX |
| Target High Price | 85.0 |
| Target Low Price | 85.0 |
| Target Mean Price | 85.0 |
| Target Median Price | 85.0 |
| Time Zone Full Name | America/New_York |
| Time Zone Short Name | EDT |
| Total Cash | 1,205,773,056 |
| Total Cash Per Share | 11.368 |
| Total Debt | 47,191,000 |
| Total Revenue | 42,156,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -5.05 |
| Trailing Peg Ratio | None |
| Two Hundred Day Average | 50.872726 |
| Underlying Symbol | CRNX |
| Uuid | 8,657b861-d8f0-3350-943c-fa486f0f26d0 |
| Volume | 8,182,078 |
| Website | https://www.crinetics.com |
| Zip | 92,121 |